ArticleOncogene2018

Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.

Sarah Yoon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.